TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17308275

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control
Number of subjects: 174
Study: 14690654

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) with a 7.5 MHz curved array transducer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 60
Study: 12214336

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox) for achalasia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox) for sphincter of Oddi dysfunction (SOD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox) for chronic anal fissure
Number of subjects: 0
Study: 9696171

Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 202
Study: 8133491

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac sodium 0.1%
Number of subjects: 0
Study: 2506598

Group type: EXPERIMENTAL
Intervention: 1 mg PO lorazepam
Number of subjects: 20
Study: 1160798

Group type: EXPERIMENTAL
Intervention: Dihydergot
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 30859545

Group type: EXPERIMENTAL
Intervention: Power plant emission reduction technologies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28570966

Group type: EXPERIMENTAL
Intervention: Family‐focused therapy for adolescents (FFT‐A) plus pharmacotherapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Brief psychoeducation (enhanced care, or EC) plus pharmacotherapy
Number of subjects: 141
Study: 25644344

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (27 g/supplement, twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soy protein supplementation (26 g/supplement, twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carbohydrate supplementation (25 g maltodextrin/supplement, twice daily)
Number of subjects: 40
Study: 23562339

Group type: EXPERIMENTAL
Intervention: Early EVAR
Number of subjects: 728

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 728
Study: 22074419

Group type: EXPERIMENTAL
Intervention: HFE variant alleles (C282Y, H63D)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Hfe(‐/‐) mice
Number of subjects: 332

Group type: COMPARATOR
Intervention: No significant intervention
Number of subjects: 332
Study: 19257898

Group type: EXPERIMENTAL
Intervention: SP-AS (sulphadoxine-pyrimethamine combined with artesunate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SP (sulphadoxine-pyrimethamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CQ (chloroquine)
Number of subjects: 0
Study: 16457914

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with patellar resurfacing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Total knee arthroplasty without patellar resurfacing
Number of subjects: 34
Study: 15193677

Group type: EXPERIMENTAL
Intervention: Levosimendan (24 microg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10828727

Group type: EXPERIMENTAL
Intervention: Ropinirole 0.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: RLS patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study: 9344297

Group type: EXPERIMENTAL
Intervention: FNS ambulation training sessions using the Parastep 1 system (32 sessions)
Number of subjects: 15
Study: 8251279

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg (Navoban)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 3546122

Group type: EXPERIMENTAL
Intervention: Brand 1 of phenytoin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brand 2 of phenytoin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brand 3 of phenytoin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brand 4 of phenytoin
Number of subjects: 60
Study: 31447402

Group type: EXPERIMENTAL
Intervention: Intelligent motion intervention system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 29864432

Group type: EXPERIMENTAL
Intervention: Dexamethasone 60 mg over 3 perioperative days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 93
Study: 26861147

Group type: EXPERIMENTAL
Intervention: Distal ultrasound-guided popliteal block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proximal ultrasound-guided popliteal block
Number of subjects: 60
Study: 25899914

Group type: EXPERIMENTAL
Intervention: Individualized loading dose (LD) regimen of cholecalciferol, 50,000 IU twice a week, followed by a monthly maintenance dose of either 50,000 or 25,000 IU
Number of subjects: 30

Group type: COMPARATOR
Intervention: Daily dose (DD) regimen of cholecalciferol, 800 IU daily for 26 weeks
Number of subjects: 30
Study: 23094678

Group type: EXPERIMENTAL
Intervention: Cued trials (AE group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: No-go trials (AE group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cued trials (CON group)
Number of subjects: 35
Study: 21134278

Group type: EXPERIMENTAL
Intervention: Educational strategy (nutritional lessons, working groups, final party)
Number of subjects: 5458

Group type: EXPERIMENTAL
Intervention: Screening strategy (detecting overweight/obesity and eating disorders, 7 group educational sessions)
Number of subjects: 5458

Group type: EXPERIMENTAL
Intervention: Environmental strategy (improving dietary and physical activity offerings in high schools)
Number of subjects: 5458
Study: 18216672

Group type: EXPERIMENTAL
Intervention: Procrit and Cell Saver
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 79
Study: 17722306

Group type: EXPERIMENTAL
Intervention: Propofol LCT with lidocaine pretreatment
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT with lidocaine pretreatment
Number of subjects: 360

Group type: COMPARATOR
Intervention: Propofol MCT/LCT without lidocaine pretreatment
Number of subjects: 360

Group type: COMPARATOR
Intervention: Propofol LCT with saline pretreatment
Number of subjects: 360
Study: 14624170

Group type: EXPERIMENTAL
Intervention: Terumo ES-H55 double-cuff sphygmomanometer
Number of subjects: 87

Group type: COMPARATOR
Intervention: Auscultatory method
Number of subjects: 87
Study: 10072024

Group type: EXPERIMENTAL
Intervention: ILMA with fiberoptic guidance (ILMA‐FOB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ILMA inserted blindly (ILMA‐Blind)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Direct laryngoscopy (laryngoscopy group)
Number of subjects: 90
Study: 8575576

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 10-80 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 20, 40, and 80 micrograms
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide doses
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 35
Study: 1827799

Group type: EXPERIMENTAL
Intervention: Acitretin (50 mg/day) plus UVB therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus UVB therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acitretin alone
Number of subjects: 0
Study: 7315712

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Urgent coronary artery bypass surgery (CABG)
Number of subjects: 190
Study: 31587979

Group type: EXPERIMENTAL
Intervention: Core decompression and PRP‐incorporated autologous granular bone grafting (treatment group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Core decompression and autologous granular bone grafting (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 31199778

Group type: EXPERIMENTAL
Intervention: Interview-based Severity of Dependence Scale (SDS)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Self-reported written version of Severity of Dependence Scale (SDS)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Comparison of interview-based SDS vs self-reported SDS
Number of subjects: 97
Study: 28324697

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (CSMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 26234800

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education and support (DSME/S) intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 23053062

Group type: EXPERIMENTAL
Intervention: 5 mg desloratadine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20 mg desloratadine
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 29
Study: 20015100

Group type: EXPERIMENTAL
Intervention: Halogen incandescent bulbs
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low-energy fluorescent tubes
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Preference for light source
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity comparison
Number of subjects: 70
Study: 19564277

Group type: EXPERIMENTAL
Intervention: Amoxicillin (90 mg/kg) with potassium clavulanate (6.4 mg/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 16303845

Group type: EXPERIMENTAL
Intervention: Metyrapone (500 mg p.o. qid for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15518626

Group type: EXPERIMENTAL
Intervention: HMR 3339 50 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HMR 3339 (other doses)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 12366646

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 28
Study: 9824802

Group type: EXPERIMENTAL
Intervention: Computerized guideline intervention for vancomycin use
Number of subjects: 1798

Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 1798
Study: 8552888

Group type: EXPERIMENTAL
Intervention: Poisson-based design for recurrent events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric tests proposed by Lawless and Nadeau
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric tests
Number of subjects: 0
Study: 2496577

Group type: EXPERIMENTAL
Intervention: Flunarizine 15 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21973

Group type: EXPERIMENTAL
Intervention: 6-valent pneumococcal vaccine
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 12-valent pneumococcal vaccine
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 523
Study: 7138751

Group type: EXPERIMENTAL
Intervention: Metoprolol SA 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol SR 200 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional Metoprolol 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8
Study: 31204321

Group type: EXPERIMENTAL
Intervention: MTA with smear layer (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTA without smear layer (Group 2)
Number of subjects: 40
Study: 30424742

Group type: EXPERIMENTAL
Intervention: Complex intervention combining behavioural support, nicotine replacement therapy, and personalized feedback on home air quality
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study: 26228466

Group type: EXPERIMENTAL
Intervention: Yoga intervention (90 min once weekly for 10 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study: 24013269

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group-based intervention (five sessions, n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (three informative sessions, n = 41)
Number of subjects: 82
Study: 23176560

Group type: EXPERIMENTAL
Intervention: Monthly motivation feedback generated by clinicians (additional to treatment as usual)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 350
Study: 20840175

Group type: EXPERIMENTAL
Intervention: Change talk 'towards change' at the end of the BMI
Number of subjects: 97

Group type: COMPARATOR
Intervention: Change talk 'away from change'
Number of subjects: 97
Study: 16740247

Group type: EXPERIMENTAL
Intervention: Long-duration alarms
Number of subjects: 85

Group type: COMPARATOR
Intervention: Short-duration alarms
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Short- and long-duration alarms from unique systems
Number of subjects: 85
Study: 15721974

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group training (CBGT) for patients with type 1 diabetes
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7
Study: 12361444

Group type: EXPERIMENTAL
Intervention: Mebendazole (n = 82)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (n = 80)
Number of subjects: 162
Study: 10102409

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7789486

Group type: EXPERIMENTAL
Intervention: 20 mg of BAY u 3405 (TP receptor antagonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg of BAY u 3405 (TP receptor antagonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg of BAY u 3405 (TP receptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2189866

Group type: EXPERIMENTAL
Intervention: Ketotifen (oral administration for 3 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketotifen (continued in open study for 15-18 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 111472

Group type: EXPERIMENTAL
Intervention: 600 microgram of synthetic TRH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 microgram of synthetic LRH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 12
Study: 31294917

Group type: EXPERIMENTAL
Intervention: Traditional risk factors only (age, sex, smoking, type 2 diabetes mellitus)
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Traditional risk factors and eleven new factors (including polypharmacy and apathy symptoms)
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Cox-regression model including traditional and new factors
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Cox-regression model accounting for competing risks
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Traditional risk factors (SBP, HDL, total cholesterol)
Number of subjects: 1811
Study: 27892839

Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse Tetric N‐Bond (Ivoclar Vivadent) with incremental technique
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse Tetric N‐Bond (Ivoclar Vivadent) with bulk-fill technique
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: self‐etch Tetric N‐Bond SE (Ivoclar Vivadent) with incremental technique
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: self‐etch Tetric N‐Bond SE (Ivoclar Vivadent) with bulk-fill technique
Number of subjects: 236
Study: 25861158

Group type: EXPERIMENTAL
Intervention: Active tDCS (11 mA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 23324510

Group type: EXPERIMENTAL
Intervention: Weight-based dosing of insulin glargine (0.5 units/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Percentage-based dosing of insulin glargine (50% of TDI)
Number of subjects: 200
Study: 21318594

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (84 μg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (84 μg)
Number of subjects: 6
Study: 19545476

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17383417

Group type: EXPERIMENTAL
Intervention: Chromoscopy with endomicroscopy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Endomicroscopy
Number of subjects: 161
Study: 15326071

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PTA+EVBT (14 Gy by gamma‐irradiation source)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PTA+EVBT
Number of subjects: 20
Study: 11312459

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine plain
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with 1:200,000 epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 40
Study: 9460345

Group type: EXPERIMENTAL
Intervention: Antibody-targeted therapies
Number of subjects: 24
Study: 8496768

Group type: EXPERIMENTAL
Intervention: Water-miscible form of vitamin E
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fat-soluble form of vitamin E
Number of subjects: 27
Study: 3440774

Group type: EXPERIMENTAL
Intervention: Single 1 g doses of cefonicid followed by ethanol challenges
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo followed by ethanol challenges
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Three consecutive 1 g doses of cefonicid given at 24 h intervals followed by ethanol challenge
Number of subjects: 15
Study: 31144363

Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Teaching sequences (not specified)
Number of subjects: 129
Study: 28243022

Group type: EXPERIMENTAL
Intervention: Immediate postoperative IOP adjustment
Number of subjects: 135

Group type: COMPARATOR
Intervention: Normal IOP (16 to 21 mmHg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Low IOP (<16 mmHg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Elevated IOP (>21 to 30 mmHg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Change in IOP from operating theater to 1 day after surgery
Number of subjects: 135
Study: 25964168

Group type: EXPERIMENTAL
Intervention: Live virus zoster vaccine (ZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22956195

Group type: EXPERIMENTAL
Intervention: Ferrous ammonium phosphate (FAP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ferrous sulfate (reference compound)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ferric pyrophosphate (FPP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of FAP to FPP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of FAP to ferrous sulfate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Relative bioavailability of FAP and FPP compared to ferrous sulfate
Number of subjects: 38
Study: 21381017

Group type: EXPERIMENTAL
Intervention: 5 μg/kg daily G‐CSF
Number of subjects: 46

Group type: COMPARATOR
Intervention: 10 μg/kg daily G‐CSF
Number of subjects: 46
Study: 19298563

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OPT)
Number of subjects: 1520
Study: 16448563

Group type: EXPERIMENTAL
Intervention: Normal overjet (Class I)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Increased overjet (Class II)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Reversed overjet (Class III)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 84

Group type: COMPARATOR
Intervention: Females
Number of subjects: 84
Study: 12953125

Group type: EXPERIMENTAL
Intervention: (131)I-M195 or (131)I-HuM195 (122-437 mCi) plus busulfan (16 mg/kg) and cyclophosphamide (90-120 mg/kg)
Number of subjects: 31
Study: 10711488

Group type: EXPERIMENTAL
Intervention: Medium-size self-inflatable bag (maximum volume, 1100 ml)
Number of subjects: 50
Study: 8622323

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (50 mg/kg intravenously)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (50 mg/kg intravenously) in children with cyanosis
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (saline) in children with cyanosis
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tranexamic acid in children with cyanosis
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo in children with cyanosis
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 88
Study: 1419816

Group type: EXPERIMENTAL
Intervention: AMSA (100 mg/m2/d on days 7, 8, and 9)
Number of subjects: 155

Group type: COMPARATOR
Intervention: No further chemotherapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: High-dose cytarabine (ara-C) (2-3 g/m2/12 h for 6 days)
Number of subjects: 155
Study: 6366660

Group type: EXPERIMENTAL
Intervention: High-dose prostaglandin E2 vaginal pessaries (3 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low-dose prostaglandin E2 vaginal pessaries (0.5 mg)
Number of subjects: 200
Study: 31790418

Group type: EXPERIMENTAL
Intervention: Traditional first-line drugs
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: C3G (third-generation cephalosporins)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: ESBL-producing isolates
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: IncHI2 plasmid carrying blaCTX-M-15
Number of subjects: 582
Study: 30234667

Group type: EXPERIMENTAL
Intervention: RCTs published in 2016
Number of subjects: 395

Group type: COMPARATOR
Intervention: RCTs published in 2010
Number of subjects: 395
Study: 26036987

Group type: EXPERIMENTAL
Intervention: Home-based educational sessions delivered by community health workers in Spanish
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116